Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $140.7 million.

  • Catalyst Pharmaceuticals' Cash from Financing Activities rose 177.90% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 90.40%. This contributed to the annual value of $140.7 million for FY2024, which is 1395.62% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Cash from Financing Activities is $140.7 million, which was up 1,395.62% from -$10.9 million recorded in FY2023.
  • Catalyst Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $140.7 million during FY2024, with a 5-year trough of -$10.9 million in FY2023.
  • Its 3-year average for Cash from Financing Activities is $43.8 million, with a median of $1.7 million in 2022.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Cash from Financing Activities slumped by 1,259.97% in 2021 and then skyrocketed by 1,395.62% in 2024.
  • Catalyst Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $702,000 in 2020, then plummeted by 1,259.97% to -$8.1 million in 2021, then surged by 120.80% to $1.7 million in 2022, then tumbled by 740.91% to -$10.9 million in 2023, then soared by 1,395.62% to $140.7 million in 2024.